Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer

被引：20

作者：

Tomasini, Pascale ^{[1
,2
,3
]}

Mascaux, Celine ^{[1
,2
,3
]}

Jao, Kevin ^{[1
,2
]}

Labbe, Catherine ^{[1
,2
]}

Kamel-Reid, Suzanne ^{[4
,5
]}

Stockley, Tracy ^{[4
,5
]}

Hwang, David M. ^{[4
,5
]}

Leighl, Natasha B. ^{[1
,2
]}

Liu, Geoffrey ^{[1
,2
]}

Bradbury, Penelope A. ^{[1
,2
]}

Pintilie, Melania ^{[6
]}

Tsao, Ming-Sound ^{[4
,5
]}

Shepherd, Frances A. ^{[1
,2
]}

机构：

[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada

[2] Univ Toronto, Dept Med, Toronto, ON, Canada

[3] Aix Marseille Univ, AP HM, Multidisciplinary Oncol & Therapeut Innovat Dept, Marseille, France

[4] Univ Toronto, Dept Pathol, Univ Hlth Network, Toronto, ON, Canada

[5] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[6] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada

来源：

CLINICAL LUNG CANCER | 2019年 / 20卷 / 03期

关键词：

Chemotherapy; Coexisting mutations; KRAS; Lung cancer; TP53; SOMATIC MUTATIONS; POOLED ANALYSIS; OPEN-LABEL; EGFR; P53; THERAPY; TRIALS; ADENOCARCINOMA; MULTICENTER; CRIZOTINIB;

D O I：

10.1016/j.cllc.2018.12.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The LACE-Bio group found adjuvant chemotherapy to be deleterious in non small-cell lung cancer with coexisting KRAS/TP53 mutations. We analyzed 218 patients with non small-cell lung cancer (28 with coexisting KRAS/TP53 mutations, 77 with TP53 mutations, 37 with KRAS mutations, and 76 with no KRAS/TP53 mutations) who received chemotherapy. There was no difference in disease-free or progression-free survival between the 4 groups. Overall survival was longer in the no KRAS/TP53 group. Background: KRAS and TP53 are common mutations in non-small-cell lung cancer (NSCLC). The Lung Adjuvant Cisplatin Evaluation Biological Program group found adjuvant chemotherapy to be deleterious in patients with coexisting KRAS/TP53 mutations. Patients and Methods: To validate these results, patients with NSCLC tested for KRAS and TP53 mutations and receiving chemotherapy for any stage NSCLC were selected. Mutation status was analyzed using next generation sequencing (Illumina) or multiplex recurrent mutation detection (MassARRAY, Agena Biosciences) assays, and was correlated with clinical and demographic data. Disease-free (DFS) or progression-free survival (PFS) was the main endpoint, and overall survival (OS) was the secondary endpoint. Results: Among 218 patients, 28 had coexisting KRAS/TP53 mutations, 77 TP53, 37 KRAS, 76 had neither KRAS nor TP53 mutation (WT/WT). There was no DFS/PFS difference for the KRASITP53 group versus all others among 99 patients who received adjuvant chemotherapy (hazard ratio [HR], 1.22; 95% confidence interval [CI], 0.61-2.44; P = .57), 27 stage III patients who received chemo-radiation (HR, 0.87; 95% CI, 0.32-2.38; P = .8), and 63 patients who received palliative chemotherapy (HR, 0.68; 95% CI, 0.31-1.48; P = .33). OS was longer in the WT/WT group compared with any other group (KRAS: HR, 1.87; 95% CI, 1.02-3.43; P = .043; TP53: HR, 2.17; 95% CI, 1.3-3.61; P = .0028; KRASITP53: HR, 2.06; 95% CI, 1.09-3.88; P = .026). No OS difference was seen for KRAS/TP53 compared with the other groups (HR, 1.26; 95% CI, 0.75-2.13; P = .38). Conclusions: There was no significant difference in DFS/PFS between the 4 groups. However, OS was longer for patients with TP53 and KRAS wild-type NSCLC who received chemotherapy for any stage compared with patients with KRAS, TP53 mutation, or double mutant tumors. (C) 2019 Elsevier Inc. All rights reserved.

引用

页码：E338 / E345

页数：8